BRPI0922305A2 - composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida - Google Patents

composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida

Info

Publication number
BRPI0922305A2
BRPI0922305A2 BRPI0922305A BRPI0922305A BRPI0922305A2 BR PI0922305 A2 BRPI0922305 A2 BR PI0922305A2 BR PI0922305 A BRPI0922305 A BR PI0922305A BR PI0922305 A BRPI0922305 A BR PI0922305A BR PI0922305 A2 BRPI0922305 A2 BR PI0922305A2
Authority
BR
Brazil
Prior art keywords
cyclophosphamide
compositions containing
containing antibodies
antitumor compositions
recognize especially
Prior art date
Application number
BRPI0922305A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI0922305A2 publication Critical patent/BRPI0922305A2/pt
Publication of BRPI0922305B1 publication Critical patent/BRPI0922305B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0922305-3A 2008-11-28 2009-11-27 Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos BRPI0922305B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291119.9 2008-11-28
EP08291119A EP2191843A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PCT/IB2009/055392 WO2010061360A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide

Publications (2)

Publication Number Publication Date
BRPI0922305A2 true BRPI0922305A2 (pt) 2016-06-21
BRPI0922305B1 BRPI0922305B1 (pt) 2022-04-05

Family

ID=40637068

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922305-3A BRPI0922305B1 (pt) 2008-11-28 2009-11-27 Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos

Country Status (29)

Country Link
US (2) US20110305690A1 (pt)
EP (2) EP2191843A1 (pt)
JP (3) JP2012510464A (pt)
KR (1) KR101749770B1 (pt)
CN (1) CN102264387B (pt)
AR (1) AR074221A1 (pt)
AU (1) AU2009321252B2 (pt)
BR (1) BRPI0922305B1 (pt)
CA (1) CA2745012C (pt)
CL (1) CL2011001256A1 (pt)
CO (1) CO6361947A2 (pt)
CR (1) CR20110283A (pt)
EA (2) EA032934B1 (pt)
EC (1) ECSP11011077A (pt)
HN (1) HN2011001426A (pt)
MA (1) MA32894B1 (pt)
ME (1) ME01139B (pt)
MX (1) MX340062B (pt)
MY (1) MY166530A (pt)
NI (1) NI201100104A (pt)
NZ (1) NZ593147A (pt)
PA (1) PA8850201A1 (pt)
PE (1) PE20110822A1 (pt)
SV (1) SV2011003925A (pt)
TW (1) TWI457346B (pt)
UA (1) UA104161C2 (pt)
UY (1) UY32267A (pt)
WO (1) WO2010061360A1 (pt)
ZA (1) ZA201103920B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX368288B (es) 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
JP7687956B2 (ja) 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL293563A (en) 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2712989C (en) * 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб

Also Published As

Publication number Publication date
CA2745012A1 (en) 2010-06-03
BRPI0922305B1 (pt) 2022-04-05
SV2011003925A (es) 2011-10-07
CR20110283A (es) 2011-09-20
AR074221A1 (es) 2010-12-29
JP6215429B2 (ja) 2017-10-18
EA201100869A1 (ru) 2011-10-31
KR20110096552A (ko) 2011-08-30
HK1164154A1 (en) 2012-09-21
CO6361947A2 (es) 2012-01-20
ZA201103920B (en) 2012-09-26
CN102264387B (zh) 2015-04-08
CL2011001256A1 (es) 2012-01-27
EA026008B1 (ru) 2017-02-28
TW201024315A (en) 2010-07-01
EP2370097A1 (en) 2011-10-05
CA2745012C (en) 2020-09-15
MA32894B1 (fr) 2011-12-01
JP2017036297A (ja) 2017-02-16
EP2191843A1 (en) 2010-06-02
EP2370097B1 (en) 2019-01-09
AU2009321252B2 (en) 2016-06-09
PE20110822A1 (es) 2011-11-22
TWI457346B (zh) 2014-10-21
HN2011001426A (es) 2014-01-13
AU2009321252A1 (en) 2010-06-03
JP2012510464A (ja) 2012-05-10
NZ593147A (en) 2012-12-21
EA032934B1 (ru) 2019-08-30
US20110305690A1 (en) 2011-12-15
EA201692041A1 (ru) 2017-05-31
ME01139B (me) 2013-03-20
MY166530A (en) 2018-07-10
CN102264387A (zh) 2011-11-30
MX340062B (es) 2016-06-23
JP2015120729A (ja) 2015-07-02
JP6018235B2 (ja) 2016-11-02
WO2010061360A1 (en) 2010-06-03
MX2011005538A (es) 2011-10-10
UY32267A (es) 2010-06-30
UA104161C2 (uk) 2014-01-10
ECSP11011077A (es) 2011-07-29
PA8850201A1 (es) 2010-07-27
NI201100104A (es) 2011-09-26
KR101749770B1 (ko) 2017-06-22
US20170056496A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
BRPI0922305A2 (pt) composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida
PT2370096T (pt) Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina
BRPI0922304A2 (pt) combinações antitumorais contendo anticorpos que especificamente reconhecem cd38 e vincristina
BRPI0914745A2 (pt) composição nutricional
BRPI0817779A2 (pt) Processamento de gás de hidrocarboneto
BRPI0915824A2 (pt) Composição nutricional contendo mistura de oligossacarídeos
AP2010005424A0 (en) Assays.
BRPI0813892A2 (pt) composições que compreendem antígenos pneumococcal
BRPI0919800A2 (pt) embalagem
BR112013014370A2 (pt) combinações antitumor que contêm anticorpos que reconhecem especificamente cd38 e bortezomib
BRPI0814745A2 (pt) Composição de produto.
BR112012003977A2 (pt) composições que induzem ajuda de célula t
ES2703158T8 (es) Composiciones farmacéuticas que comprenden oxi-hidróxido de hierro
IT1394472B1 (it) Tavolo per riunioni.
BRPI0920653A2 (pt) embalagem
BRPI0821907A2 (pt) Composições de siloxano
BRPI0923428A2 (pt) refinaria de gás integrada
BRPI0906812A2 (pt) Mitigação de reluzência do lcd.
BR112012012892A2 (pt) misturas estabilizadas que contêm modificadores de fricção.
DE602008004219D1 (de) Packung für rauchartikel
BRPI0914940A2 (pt) composições nutritivas contendo punicalaginas
IL219470A (en) Antibacterial antibody, preparations containing it and its uses
BRPI0906828A2 (pt) Embalagem
BRPI0907448A2 (pt) Instrumentos.
PT2362778T (pt) Composições que compreendem vitamina c

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25G Requested change of headquarter approved

Owner name: SANOFI (FR)